Here is my post for anyone who doesn't go to the other
Here is my post for anyone who doesn't go to the other board.
Ideas Conference from my view and responses to all that replied to JB. I have limited posts so I will and answer everything in this post
I think that JB's view of the conference and our conversations with Dr. Menon, Dr. Holden, and Dr. Kumar was very similiar to mine.
All 3 of them diplayed an overall quiet confidence & excitement in how not only the Trial was progressing, but how Cellceutix was moving on all fronts. All 3 were willing to engaged in conversation and talk about not only Kevetrin but anything Cellceutix. As Dr. Holden talked about in the Presentation they all were deeply saddened from the loss of Dr. Frei and talked about how lucky they were to work so close with him.
They (like all of us) are waiting for the results of the P21 test. I agree with JB about his take on this. They seemed happy with the way the trial was going and understand that delays happened and they are looking forward to the results also. Dr. Menon explained that when doing the test with animals everything is much more controlled and much easier to keep on track. In animals everything can happened like clockwork in reference to dosing and testing. It does not happened this way in a human trial. They are constantly checking with how the patient is feeling and act accordingly. These are sick people and they deserve the best treatment possible.
They also explained how the chemo and radiation is like bombing the cancer and damaging many innocent bystanders. Very similar to The Progressive SA Article and how Kevetrin goes in and retrains the cells on how to fix themselves.
Reply responses....
Petermantx.... In refece to the stock price I agree. When I left the conference and check on the SP (down .18 at the time) I was first shocked and them quickly felt calm because these short term fluctuations have no effect on my long term view. I just left a conversation that increased my long term confidence in Cellceutix.
Cabel.... No one asked about Leo not being there except for JB. They said he had a scheduling conflict that he could not change. I for one was expecting to see Leo (just my thought going into it) not Dr. Menon at the conference and I was surprised to see Dr. Menon when he walked in the door. He was very engaging from the start. We talked for a few minutes before the presentation and again after. I did not take it as a positive or a negative to the fact that Leo was not there. I take it as he had a conflict and could not make it.
farrell90.... All three Dr. were well aware of the asset of having KARD labs relationship to CTIX. Dr. Holden actually mentioned in conversation how "CTIX is a lean mean machine". Not only in reference to Kard, but with the Advisory Board that they have assembled. CTIX does seem to have a bright future with the current pipeline and the possible future compounds.
Tails....The overall interest level of the attendees I am not sure. The presentations were 1/2 long and we left the room right after CTIX, hoping to talk more with the DR.'s.
Steelyeye..... The "Tone" as I said above a quiet confidence. And I would add a genuine passion for there work.
JB3729 posted......
Met up with grayhound this morning at the IDEAS Conference. We were fortunate enough to speak with Dr. Menon, Dr. Holden, and Dr. Kumar for 15 or 20 minutes after the presentation.
I am very impressed by these individuals. They appeared to be confident and energetic. Dr. Holden is now a full time CTIX employee. Dr. Kumar is a full time Kard Scientific employee along with 80-90 others.
Dr. Menon is aware of the Breakthough Therapy Designation given to ScioDerm after a Proof of Concept trial (see post 30099). He said this is our plan for Prurisol should things work out.
Ctix has a new anti- cancer drug that has shown "remarkable early results".
Kevetrin is one of about 30 anti-cancer compounds that CTIX has tested. Dr. Menon said it's still too early to tell whether Kevetrin will work best alone or in conjunction with other drugs. He said that Kevetrin started out as a drug to be used along with radiation . Then, thanks in large part to Dr. Kumar, evolved into what it is today. The doctors stressed how revolutionary Kevetrin is, in that it restores the body's ability to fight cancer .
They are eagerly awaiting the p21 data release and hope it will happen soon. We couldn't get much more than that, except, Dr. Holden said the scientific community likes to do things in 3's. I interpreted that to mean data from 3 cohorts.
Today was a great experience!
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Fresh Leadership at Northern Jet Well, if you didn’t see this coming, you’ve been snoozing on the tarmac. Northern Jet, no stranger to the skies after three decades, just roped in Matthew Harris as their new CEO from October 2, 2026. They're pulling in this hotshot with more than 25 years riding the turbulence of private aviation. And listen to this: his marching...
Continue Reading
The Gadget You Didn't Know You Needed Ever feel that momentary panic when your wallet seems to have vanished into thin air? ROKFORM's fresh offering, the Signal Card, tackles that heart-stopping moment head-on. They've taken the mundane act of misplacing your wallet and transformed it with their sleek, credit-card-sized tracker. This baby pairs seamlessly with Apple Find...
Continue Reading
Soundproofing Takes Off in Brazil Skandia has just pulled off a neat trick, earning the nod from Brazil's National Civil Aviation Agency (ANAC) for their King Air soundproofing kit. That means quieter skies ahead for operators of the King Air 200 and 300 series in Brazil. This is no small feat, folks; it's like finally getting that coveted backstage pass after years of...
Continue Reading
Bringing Capital and Content Under One Roof There's something in the air as Itibari-Waynne & Partners (IWP) team up with the VYRE Network to crank out a fresh slate of content for VYRE Business News Global (VBNGtv). This partnership ain't just another splash in the buzzy world of digital media; it's like merging Wall Street with Hollywood. IWP, prepping to go full...
Continue Reading
Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...
Continue Reading
HITRUST i1 Certification: The Gold Standard in Security For a world increasingly reliant on digital infrastructure, cybersecurity certification is no longer just a badge of honor; it's a cornerstone of trust. Dentistry.One nailed this down by bagging that coveted HITRUST i1 certification. When folks talk about securing data, HITRUST might as well be speaking gospel. We're...
Continue Reading
A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...
Continue Reading
Has anyone else noticed just how fast the world spins when it comes to consumer trends these days? Bob Evans is hopping right on the protein bandwagon with its latest launch, a microwave-ready Protein Macaroni & Cheese that packs 18 grams of protein per serving. You gotta hand it to them for seizing opportunity when they see it. This one's not just about tossing a new...
Continue Reading
Change of Guard in Cardiac Health at Karoo Here's a move that might shake things up in the healthtech sector: Karoo Health just snagged Angela "Angie" Breton as their new Chief Commercial Officer. It's like putting a seasoned captain at the helm right before setting sail on uncharted waters. Breton's not just any captain—she's got a hefty 25 years of experience...
Continue Reading
The Urgency of Liver Cancer Awareness Death doesn’t wait, does it? When liver cancer is the villain in question, every moment becomes precious because this beast doesn’t roar until it’s too late. Here we are in 2026, staring at nearly 31,000 annual deaths in the U.S. alone. But hope flickers with a new congressional resolution aiming to slap a bright spotlight on...
Continue Reading
Top 5 Most Recently Viewed Articles
Brighton Marine Awarded DoD Contract for Health Care Services Brighton Marine, Inc., a renowned non-profit organization dedicated to improving healthcare and housing for service members and veterans, has recently received a significant contract from the Department of Defense (DoD) to offer comprehensive health care services. This initiative will be executed under the...
Continue Reading
McDonald's Stellar Growth Over Two Decades McDonald's (NYSE: MCD) has exhibited impressive growth throughout the last 20 years. Investors who placed their trust in this iconic fast-food chain have witnessed substantial returns. On average, McDonald's has outperformed the market with an annualized return of 11.64%, which is notably higher than many other investment...
Continue Reading
Norcros plc Invites You to Their 2024 Interim Results Webinar Norcros plc, a prominent group that specializes in innovative bathroom and kitchen products, is hosting a webinar to discuss their interim results for 2024. The live event will feature insights from Thomas Willcocks, the CEO, and James Eyre, the CFO. It is scheduled to take place through the Engage Investor...
Continue Reading
ReTo Eco-Solutions Faces Nasdaq Delisting with Appeal Plans ReTo Eco-Solutions, Inc. (NASDAQ: RETO), a frontrunner in manufacturing equipment for the production of eco-friendly materials, has recently encountered a significant challenge. The Company received a delisting determination from The Nasdaq Stock Market, which notified ReTo that its Class A shares have been...
Continue Reading
RIVANNA Receives $800,000 Grant for Ultrasound Technology RIVANNA, the pioneering developers of advanced imaging-based medical technologies, has successfully secured an $800,000 grant from the Virginia Catalyst Program. This funding is earmarked for the enhancement and clinical development of the Accuro 3S diagnostic ultrasound system, which is designed specifically for...
Continue Reading